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Abstract
The receptor for advanced glycation end products (RAGE) is thought to be involved in the pathogenesis of a broad range of
inflammatory, degenerative and hyperproliferative diseases. It binds to diverse ligands and activates multiple intracellular
signaling pathways. Despite these pivotal functions, molecular events just downstream of ligand-activated RAGE have been
surprisingly unknown. Here we show that the cytoplasmic domain of RAGE is phosphorylated at Ser391 by PKCf upon
binding of ligands. TIRAP and MyD88, which are known to be adaptor proteins for Toll-like receptor-2 and -4 (TLR2/4),
bound to the phosphorylated RAGE and transduced a signal to downstream molecules. Blocking of the function of TIRAP
and MyD88 largely abrogated intracellular signaling from ligand-activated RAGE. Our findings indicate that functional
interaction between RAGE and TLRs coordinately regulates inflammation, immune response and other cellular functions.
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Introduction
The receptor for advanced glycation end products (RAGE) is a
type I single-pass transmembrane protein belonging to the
immunoglobulin superfamily [1]. RAGE is thought to be involved
in a broad range of inflammatory, degenerative and hyperproli-
ferative diseases, including sepsis, rheumatoid arthritis, diabetic
nephropathy, atherosclerosis, cancer, and neurological disorders
[2–5]. The receptor is composed of an extracellular region (one V-
type and two C-type immunoglobulin domains), a hydrophobic
transmembrane-spanning domain, and a short cytoplasmic tail.
The extracellular domain can bind diverse ligands, including
advanced glycation end products (AGEs) [2], high-mobility group
box 1 (HMGB1) [6], S100 family proteins [7], and amyloid fibrils
[8].
Binding of ligands to RAGE leads to activation of multiple
signaling pathways, including signaling pathways involved in the
production of reactive oxygen species, Ras-mediated extracellular
signal-regulated kinase 1/2 (ERK1/2), Akt, stress-activated
protein kinase/c-Jun-NH2-terminal kinase (SAPK/JNK), p38
MAP kinase, small GTPase Cdc42/Rac1, and NFkB and AP-1
transcription factors [9–13]. In accordance with this, cellular
biological outcomes are also diverse and include induction of
apoptosis, hyperproliferation, increased motility, and production
of inflammatory cytokines [4,5,14]. It is intriguing that different
RAGE ligands often show different effects in a given type of cell.
For example, we previously showed that dimerized S100A11
activated Akt and induced production of EGF, thus stimulating
growth of normal human keratinocytes via RAGE [15]. In the
same cells, S100A8/A9, which is known to be a RAGE ligand
[16], enhanced production of proinflammatory cytokines includ-
ing IL-8, IL-1F9 and TNFa but neither induced EGF nor
activated Akt [17].
RAGE has a short cytoplasmic domain (41 amino acids), from
which RAGE-triggered signaling is initiated. The cytoplasmic
domain has no obvious signaling domain or any motifs known for
receptor signaling. Hudson et al. identified Diaphanous-1 (Dia-1)
to be a binding partner to the RAGE cytoplasmic domain by
employing a yeast two-hybrid method [18]. Dia-1 is required for
controlling the activation of Rac-1 and Cdc42, resulting in
promotion of cellular migration. It is unclear, however, whether
diverse downstream signaling pathways of RAGE are controlled
by Dia-1 alone. Ishihara et al. [19] reported that extracellular
signal-regulated protein kinase-1 and -2 (ERK1/2) bind to the
cytoplamic domain of RAGE, but the biological significance of the
interaction was not clarified. It remains a major challenge to reveal
how the cytoplasmic domain of RAGE is activated upon ligand
binding and how its activation is transduced to downstream
signaling molecules for biological significance of RAGE in normal
and pathological circumstances.
In the present study, we focused on molecular events in and at
the cytoplasmic domain of RAGE. We found that the cytoplasmic
domain of RAGE was phosphorylated at Ser391 by PKCf upon
binding of ligands. To our surprise, TIRAP and MyD88, which
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phosphorylated RAGE and transduced a signal to downstream
molecules. The findings indicate that functional interaction
between RAGE and TLRs coordinately regulates inflammation,
immune response and other cellular functions.
Results
Cytoplasmic Domain of RAGE Is Phosphorylated by PKCf
upon Ligand Binding
We first examined whether the cytoplasmic domain of RAGE is
phosphorylated. Overexpression of full-length RAGE but not that
of a cytoplasmic domain-deleted construct resulted in phosphor-
ylation in HEK293 cells, to which known RAGE ligands including
S100A11, S100A12 and HMGB1 were applied (Figure 1A).
Extent of the phosphorylation was S100A11 dose- and time-
dependent (Figures S1A and S1B). Phosphorylation of RAGE was
observed also upon stimulation of another RAGE ligands,
S100A8/A9 (Figure S1C).
Since the cytoplasmic domain of RAGE lacks any potential
kinase domain, we screened for a protein kinase(s) that can
phosphorylate recombinant RAGE in vitro and identified PKCa
among representative kinases examined (Figures 1B and S1D).
Screening of PKC isotypes resulted in identification of PKCf to be
the most probable candidate for phosphorylation of RAGE
(Figure 1C). Down regulation of endogenous PKCf but not that
of PKCa, PKCe and PKCm abrogated S100A11-induced
phosphorylation of RAGE in
32P-orthophosphate-labeled HEK
293 cells (Figure 1D). The specific siRNA against PKCf also
effectively inhibited S100A8/A9-induced phosphorylation of
RAGE (Figure S1H). Endogenous PKCf was activated by RAGE
ligands such as S100A11, S100A12, HMGB1 and AGE in RAGE-
transfected HEK293 cells as demonstrated by an in vitro assay
showing phosphorylation of a PKCf-specific substrate (Figure
S1E) by the cell extracts (Figure 1E). Activity of PKCf was
dependent on dose of the ligands (Figure S1F). Extracts prepared
from HEK293 cells transfected with cytoplasmic domain-deleted,
hence signal transduction-deficient, RAGE did not show such an
activity (Figure 1E).
The cytoplasmic domain of human RAGE has 4 potential
phosphorylation sites, i.e., Ser391, Ser399, Ser400, and Thr401.
Among the 4 potential phosphorylation sites of the cytoplasmic
domain of RAGE, only Ser391 is conserved among humans, mice,
Guinea pigs, rats, rabbits, dogs, and cats. Replacement of Ser391
with Ala, but not any of the other 3 residues, resulted in
abrogation of phosphorylation by PKCf in vitro (Figure 1F).
Overexpressed wild-type RAGE but not the Ser391-replaced
variant was phosphorylated in HEK293 cells when S100A11 was
applied, while binding of PKCf to RAGE was independent of the
phosphorylation status (Figure 1G and S1G). These results
indicated that RAGE is phosphorylated at Ser391 by PKCf upon
ligand binding.
TIRAP binds to cytoplasmic domain of RAGE and
transduces a signal from ligand-activated RAGE
The nature and functional mode of possible adaptor proteins for
RAGE are not well understood. Our trial screening for proteins
that bind to the cytoplasmic domain of RAGE by immunopre-
cipitation followed by mass spectrometry failed in identification of
any promising candidates. We changed the strategy to a
candidate-based screening partly because of implicated functional
similarity between RAGE and TLRs [20]. Use of a potent
expression vector and optimization of tags to express the short
Figure 1. RAGE is phosphorylated at Ser391 by PKCf upon
ligand binding. (A) Phosphorylation of full-length RAGE (wt, closed
arrowhead) but not cytoplasmic domain-deleted RAGE (DCyt: open
arrowhead). HEK293 cells were transfected with epitope-tagged RAGE
constructs (RAGE-Myc-HA-Flag-6His), [
32P]phosphate-labeled, and treat-
ed with the ligands (10 ng/ml, 1 h), and then RAGE proteins were pulled
down with anti-HA antibody (clone HA-7)-agarose before Western
blotting and autoradiography. The results were confirmed by five similar
experiments. (B and C) Phosphorylation of RAGE(Cyt) in vitro. 6His-2HA-
RAGE(Cyt) purified from transfected HEK293 cells by anti-HA antibody
(clone HA-7)-agarose was incubated with constitutively active recombi-
nant kinases of commercial source. Western blotting with anti-HA and
anti-6His antibodies was performed for determination of amounts of
RAGE(Cyt) and kinase proteins, respectively. The results were confirmed
by five similar experiments (B) or by an independent and four related
experiments (C). (D) Down-regulation of endogenous PKCf but not of
other isoforms by siRNA abrogated S100A11 (10 ng/ml, 6 h)-induced
phosphorylation of co-transfected RAGE-Myc-HA-Flag-6His in HEK293
cells.Theresults arerepresentativeofthreeindependentexperiments. (E)
Activation of endogenous PKCf by RAGE ligands. HEK293 cells
transfected with RAGE-Myc-HA-Flag-6His (wt or DCyt) were treated with
10 ng/mlofGST, S100A11,S100A12,andHMGB1or100 mg/ml ofAGE for
1 h. Cell extracts were incubated with a specific PKCf-substrate in the
presenceof [c-
32P]-ATP.Theexperimentwas performed in quadruplicate,
and the results were confirmed by three related experiments. (F)
Determination of phosphorylation site of RAGE(Cyt). Recombinant PKCf-
6His (top panel) was incubated with isolated variants of 6His-2HA-
RAGE(Cyt) [SSST (wild-type), ASST (Ser391 to Ala), SAST (Ser399 to Ala),
SSAT (Ser400 to Ala), SSSA (Thr401 to Ala)] and assayed as for (B) and (C).
The results were confirmed by an independent and two related
experiments. (G) S100A11 (10 ng/ml)-dependent phosphorylation of
transfected 6His-2HA-RAGE(wt) at Ser391 in HEK293 cells. [
32P]Phos-
phate-labeled cell extracts were pulled down with anti-HA agarose and
immunoblotted with anti-6His antibody (top) or analyzed by autoradi-
ography (middle). Co-precipitated endogenous PKCf was detected with
anti-PKCf antibody (bottom). The results were confirmed by an
independent and five related experiments.
doi:10.1371/journal.pone.0023132.g001
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TIRAP as an adaptor protein for RAGE (Figure S2A).
TIRAP and MyD88, but not TRAM, were co-precipitated with
overexpressed RAGE and RAGE was phosphorylated in HEK293
cells predominantly when the cells were treated with RAGE
ligands, S100A11, S100A12, HMGB1 and AGE but not with a
TLR4 ligand (LPS) and TLR2 ligands (Figure 2A). TLR2/4
blocker mixture did not affect ligand-induced activation of RAGE
and its downstream signaling. The amount of TIRAP and MyD88
co-precipitated with the cytoplasmic domain of RAGE was shown
to depend on phosphorylation status of Ser391 as demonstrated
using phosphorylation-mimic and non-phosphorylatable variants
(Figure S2B). In HEK293 cells, endogenous TIRAP, MyD88, and
IRAK4 were co-precipitated with overexpressed wild-type RAGE
but not with a non-phosphorylatable variant when the transfected
cells were treated with AGE (Figure 2B). In accordance with this,
downstream signal tansducers of TIRAP including Akt, p38,
IKKa,N F kB, and caspase 8 were activated, as demonstrated by
elevated phosphorylation levels for Akt, p38 and IKKa, increase
in the amount of the truncated form for caspase 8, and increase in
binding to NFkB-responsible element for NFkB (Figure 2C).
Mutation in a protein-protein interaction domain of TIRAP
resulted in loss of not only its binding to RAGE but also that of
wild-type MyD88 (Figure S2C), indicating that MyD88 binds to
RAGE only in the presence of TIRAP. Binding of TIRAP to the
cytoplasmic domain of RAGE was confirmed to be direct using
both recombinant proteins (data not shown). This mode of
interaction is similar to that known for TLR2/4, TIRAP, and
MyD88 [21]. Essential nature of TIRAP and MyD88 for RAGE
signaling was demonstrated using TIRAP-down regulated
NIH3T3 cells and MyD88-/- mouse fibroblasts (Figures S2D,
2D and 2E). Overexpression of TIRAP or MyD88 rescued the
defective protein interaction and signal transduction in corre-
sponding cells. These results indicate that TIRAP and MyD88
function as essential adaptor proteins for RAGE, binding to
ligand-activated phosphorylated RAGE and transducing a signal
from it.
Signal transduction from activated endogenous RAGE
and its biological consequence in human umbilical vein
endothelial cells (HUVECs)
We next examined activation and downstream signaling of
endogenous RAGE using HUVECs. RAGE was expressed in
HUVECs (Figure S3A). When HUVECs were exposed to AGE,
the downstream signaling molecules from RAGE were activated in
dose- and time-dependent manners (Figures S3B and S3C).
Nuclear translocation of NFkB induced by AGE was abrogated by
treatment with inhibitor peptides for MyD88 and TIRAP (Figure
S3D). Application to HUVECs with RAGE ligands such as
S100A11, S100A12, HMGB1, and AGE but not LPS and TLR2
ligands induced phosphorylation of endogenous RAGE, interac-
tion with TIRAP, MyD88, and IRAK4, and transduction of signal
to the downstream molecules (Figures 3A and 3B). A mixture of
TLR2/4 blockers showed no effect on these processes. Activation
of the molecules downstream from RAGE was abrogated by
treatment of HUVECs with inhibitor peptides for MyD88 and
TIRAP and siRNA for PKCf (Figures S3F and S3G). On the
other hand, LPS did not induce phosphorylation of RAGE and its
interaction with the adaptor proteins (Figures 3A and S3F) but
activated the downstream molecules from TIRAP since TLR4
shares the adaptor protein with RAGE (Figures 3B and S3G).
Endogenous PKCf was activated by RAGE ligands and the
activation was canceled by down regulation of RAGE using
siRNA in HUVECs (Figure S3H).
It is well known that AGE induces IL-6 in endothelial cells
through binding to RAGE [22]. Application of AGE to HUVECs
resulted in induction of IL-6 mRNA, which was abrogated by
pretreatment of the cells with inhibitory peptides for TIRAP and
MyD88 (Figure 3C). When AGE was applied to a co-culture of
HUVECs and human arterial sooth muscle cells (HASMCs), AGE
induced IL-6 selectively in HUVECs (Figure 3D). HASMCs did
not express RAGE at any appreciable levels (Figure S3A). A wider
screening using an antibody array showed that angiogenin, BDNF,
EGF, IL-1a, IL-1b, MIP3a, PDGF-BB, and RANTES in addition
to IL-6 were induced by AGE in HUVECs and that the induction
was abrogated by an inhibitor peptide for MyD88 (Figure 3E).
Another well-known effect of AGE on endothelial cells is induction
of apoptosis [23]. Application of AGE to HUVECs resulted in
increase in annexin V-positive cell rate, which was abrogated by
inhibitor peptides for TIRAP and MyD88 and by siRNA for
PKCf (Figure S3I). These results indicate that the signal
transduction pathway we found in the present study, i.e.,
phosphorylation of RAGE by PKCf and function of TIRAP
and MyD88 as adaptor proteins, endogenously works in
HUVECs, which are one of the most critical target cells of RAGE
activation in physiological and pathological contexts.
Effect of differential stimulation of RAGE and TLR4
Since TIRAP and MyD88 function as adaptor proteins for
TLR2/4, we next examined the mode of signal transduction when
RAGE and TLR4 were differentially stimulated. AGE and LPS
pre-incubated with LBP for efficient transfer of LPS to the
receptor [24] were used to selectively stimulate RAGE and TLR4,
respectively, and a mixture of LPS and HMGB1 [25] or S100A8
and S100A9 (S100A8/A9) [17] were used to simultaneously
stimulate both receptors. Since CD14 and MD2 have been shown
to be involved in activation of TLR4 by ligands [26], we used
HEK293 cells constitutively expressing both genes.
Immunoprecipitation using antibodies against respective tags of
TLR4 and RAGE followed by Western blot analysis showed that
RAGE was co-precipitated with TIRAP, MyD88 and IRAK-4,
while TLR4 was co-precipitated with TRAM in addition to the
three proteins only when the receptors were activated by the
ligands (Figure 4A and S5B). In accordance with the binding mode
of adaptor proteins to respective receptors, downstream signaling
molecules were activated (Figure S4A and S5A). Mutations in a
protein-protein interaction domain, Toll/IL-1R intracellular
domain (TIR), of RAGE and TLR4 (Figures S4B, S4C, and
S5C) resulted in abrogation of binding to the adaptor proteins and
downstream signal transduction (Figures 4B, 4C, S5C, and S5D).
Activation of Rac1 and NFkB and phosphorylation of Akt, p38,
JNK, and IKKa/b were observed when either RAGE or TLR4
was stimulated (Figures 4C, S4A, S4D, S5A, and S5D).
Phosphorylation of IRF-3 was enhanced by stimulation of TLR4
but not by stimulation of RAGE (Figures 4C, S4A, S4D, S5A, and
S5D). This is conceivable because IRF-3 is a downstream effector
of TRAM and all other signaling molecules examined are
downstream to TIRAP/MyD88 [27,28]. Addition of polymixin
B blocked effect of LPS but not that of AGE (Figure S4D). IL-6,
IL-8 and TNFa were induced by a ligand that can bind to either
RAGE or TLR4, but interferon b (IFNb) was induced only by a
TLR-ligand, HMGB1/LPS (Figure 4D). It is notable that the
extent of activation of the signaling molecules and induction level
of the target genes were higher when both receptors were
simultaneously stimulated than that observed with stimulation of
an individual receptor. These results indicate that activation of
TIRAP/MyD88 triggers similar downstream signaling pathways
irrespective of their binding partners.
TIRAP Functions as an Adaptor Protein for RAGE
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The findings described above clearly demonstrate that TIRAP
and MyD88 function as adaptor proteins for RAGE as well as for
TLR2/4 (Figure 5). The recruitment of the adaptor proteins
induced further recruitment of IRAK4, which in turn activated the
downstream effecter kinases such as Akt, p38, JNK and IKKs and
ultimately led to the induction or inflammatory cytokines, IL-6,
IL-8, and TNFa through activation of NFkB. On the other hand,
IFNb was not induced by RAGE ligands. This result may be due
to the lack of interaction between the cytoplasmic domain of
RAGE and TRAM (Figure 2A). We previously showed that
S100A11 could activate Akt via RAGE in keratinocytes [15]. This
is probably mediated by MyD88, since MyD88 is known to
directly interact with and activate the downstream effector kinase
Akt [28].
Ligand-induced phosphorylation of RAGE at Ser391 is a
prerequisite for efficient recruitment of the adaptor proteins. The
phosphorylation was mediated by the PKCf (Figure 1) through
binding with the cytoplasmic domain of RAGE (Figure S1G).
Kinase activity of PKCf was also remarkably upregulated by
stimulation of HEK293 cells with diverse RAGE ligands and of
primary normal human endothelial cells (HUVECs) with AGE.
AGEs are non-enzymatical adducts of proteins formed in pro-
oxidant and hyperglycemic environments [2,3,23]. Treatment of
the endothelial cells with AGE induced apoptosis (Figure S3I)
Figure 2. TIRAP and MyD88 function as adaptor proteins for RAGE. (A) Co-precipitation of endogenous TIRAP and MyD88 but not TRAM
with recombinant RAGE(wt). HEK293 cells were transfected with RAGE(wt) and RAGE(DCyt) tagged with -Myc-HA-Flag-6His, [
32P]phosphate-labeled,
and treated with AGE at 100 mg/ml or with other ligands at 10 ng/ml for 1 h. TLR2/4 blocking mixture (Mixture, see Materials and Methods) was
preincubated with the ligands for 30 min at room temperature. Cell extracts were analyzed by Western blotting with or without prior
immunoprecipitation and by autoradiography. The results were confirmed by 7 related experiments. (B and C) AGE (100 mg/ml)-induced
phosphorylation of RAGE at Ser391 is essential for recruitment of endogenous TIRAP and MyD88 (B: The results were confirmed by an independent
and two related experiments.) and downstream signal transduction (C: The results were confirmed by an independent and two related experiments.)
in HEK293 cells. Full-length 6His-2HA-RAGE constructs were used. SSST, wild-type; ASST, Ser391 to Ala. (D and E) Abortive signal transduction from
activated endogenous RAGE in MyD88-/- or TIRAP-down regulated mouse fibroblasts was rescued by forced expression of the corresponding human
genes. Mouse TIRAP siRNA and expression vectors were transfected 48 h before treatment with AGE (100 mg/ml, 1 h). Experiments were performed
under the conditions similar to those described in (A) except for immunoprecipitation using a biotinylated antibody against endogenous RAGE.
32P
shows the results of autoradiography of the immunoprecipitated RAGE. The results were confirmed by an independent and two related experiments.
doi:10.1371/journal.pone.0023132.g002
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S3C). Notably, this effect was almost completely inhibited by
siRNA for PKCf and the inhibitor peptides for TIRAP and
MyD88 (Figure S3I), indicating the critical role of these proteins
in RAGE-mediated apoptotic cell death. Hence, diabetes-
associated vascular damages through AGE-RAGE interaction
are probably mediated by TIRAP and MyD88. It remains to be
clarified how ligand-activated RAGE led to activation of PKCf
PKCf requires activated Ras, a small GTPase, for its own kinase
activity [29]. Lander et al. [9] reported that AGE-albumin
activated p21 (ras) in rat pulmonary artery smooth muscle cells
that express RAGE.
Hudson et al. [18] showed by immunoprecipitation that the
RAGE cytoplasmic domain interacts with the FH1 domain of
Dia-1 and that down-regulation of Dia-1 blocks RAGE-
mediated activation of Rac-1 and Cdc42 and RAGE ligand-
stimulated cellular migration. We could not detect endogenous
Dia-1 protein in immunoprecipitates prepared from HEK293
cells using an antibody against tagged RAGE under the
conditions in which endogenous TIRAP and MyD88 were co-
precipitated with overexpressed RAGE. In accordance with the
results by Hudson et al., however, overexpressed FH1 domain of
Dia-1 was co-precipitated with the cytoplasmic domain of
RAGE (data not shown). In addition, our preliminary data
suggest that TIRAP and the FH1 domain of Dia-1 compete for
binding to the cytoplasmic domain of RAGE. Precise interac-
tion among the three proteins remains to be elucidated.
Binding of TIRAP but not MyD88 to the cytoplasmic domain
of RAGE was confirmed to be direct by an in vitro protein
interaction assay using recombinant proteins (data not shown).
Phosphorylation of RAGE at Ser391 greatly enhanced affinity to
TIRAP (Figure 2), indicating that more negative charge at the
residue 391 is important for efficient binding with TIRAP. When
the residue is phosphorylated, Q(390)SEE becomes equivalent to
QEEE. Intriguingly, the motif of Q followed by 3 successive
negatively charged residues is found at another site of RAGE
(QEEE stating at 379) and in the cytoplasmic domain of TLR4
(QDED starting at 683) and in TLR2 (QELE starting at 661) but
not of TLR1 and TLR3. The motif might play a role in
interaction of intracellular domains of receptors and TIRAP.
Figure 3. Specific activation of endogenous RAGE by AGE induced cytokines in HUVECs. (A and B) Activation of downstream signaling
molecules by specific activation of endogenous RAGE. Experiments were performed under the conditions similar to those described in Fig. 2A except
for down regulation of RAGE with siRNA, immunoprecipitation using an antibody against RAGE, and type of cells used. The results were confirmed by
an independent and two related experiments (A) or by an independent and three related experiments (B). (C) Induction of IL-6 by AGE (100 mg/ml for
12 h) demonstrated by Northern blot analysis in HUVECs in serum- and supplement-free conditions. Cell-permeable inhibitory peptides (100 mM)
were added 12 h prior to the addition of AGE. The results were confirmed by two independent and one related experiments. (D) Induction of IL-6 in
HUVECs but not in HASMCs by treatment with AGE. HUVECs co-cultured with HASMCs pre-infected with an adenovirus carrying GFP were treated
under conditions similar to those described in (C). Fixed cells were immunostained with anti-IL-6 antibody. Bars, 20 mm. The results were confirmed
by three independent experiments. (E) Detection of cytokines secreted into the medium by HUVECs treated with AGE using an antibody array
[Human cytokine Antibody Array VI & 6.1 (60), RayBiotech, Norcross GA]. Dotted squares indicate antibodies against corresponding cytokines. Cells
were treated under conditions similar to those described in (C). The results were confirmed by an independent experiment.
doi:10.1371/journal.pone.0023132.g003
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23132Figure 4. Behavior of adaptor proteins and signal transduction upon differential stimulation of RAGE and TLR4. (A) Co-precipitation
of endogenous adaptor proteins with full-length 6His-2HA-RAGE(wt) and TLR4(wt)-Myc transfected into 293-hMD2-CD14 cells. The cells were treated
with control BSA (100 mg/ml), LBP-LPS (100 ng/ml each, preincubated for 2 h), AGE (100 mg/ml), and HMGB1-LPS (100 ng/ml each, preincubated for
2 h) for 30 min. Cell extracts were pulled down with anti-Myc + anti-HA, anti-Myc, or anti-HA agarose and immunoblotted with indicated antibodies.
Open triangle, TLR4; closed triangle, RAGE. The results were confirmed by two independent and two related experiments. (B) Co-precipitation of
endogenous adaptor proteins with RAGE-Myc-HA-Flag-6His and TLR4-Myc (w, wild-type; D, cytoplasmic domain-deleted variant). Experiments were
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23132Sharing of the adaptor proteins between RAGE and TLR2/4 is
unexpected but not inconceivable. RAGE and TLR2/4 are
categorized as pattern-recognizing receptors, and they use NFkB
as a major intracellular signaling molecule and are involved in
diverse cellular functions, inflammation in particular. Lin
indicated the possibility that a TIR-containing protein may
function as an adaptor protein for RAGE [20]. TLR4 has a
signal transduction pathway of TRAM-TRIF in addition to
TIRAP-MyD88 [30,31]. It is not yet clear whether Dia-1 is
another arm for RAGE. Both RAGE and TLR2/4 have common
and distinct ligands. Our findings indicate that RAGE and TLR2/
4 partly share an intracellular signaling pathway.
It is intriguing that different RAGE ligands often show different
effects in given types of cells. One reason may come from
simultaneous binding of RAGE ligands to TLR2/4 as described
above. A complex of S100A8 and S00A9 (S100A8/A9) also binds
both RAGE and TLR4 [5,16,32,33]. S100A8/A9 induced
phosphorylation of RAGE (Figures S1C and S1H) and led to
activation of diverse signal effectors such as Rac1, Akt, p38, JNK,
IKK, and NFkB (Figure S5A and S5D). On the other hand,
recruitment of the adaptor proteins triggered by S100A8/A9 was
limited (Figure S5B and S5C). In addition, activation of p38, JNK,
IKK, and NFkB was not completely inhibited by co-expression of
RAGE- and TLR4-dominant negative forms, contrary to the
complete inhibition observed when treated with HMGB1-LPS
(Figure S5D). This may be explained by presence of other
unidentified receptor(s) for S100A8/A9 in addition to RAGE and
TLR4.
Apparently, the system involving ligands-receptors-adaptor
proteins for RAGE and TLR2/4 is very complicated. Further
extensive studies are needed to clarify the functional interaction of
proteins in the system and biological outcomes of such
interactions. Studies in this direction will ultimately lead to better
understanding of and development of therapeutic measures for
many serious human diseases including diabetes mellitus and
cancer [2–5,11,34–36].
Materials and Methods
Cells and Chemicals
Cell lines of HEK293, NIH3T3 (ATCC, Manassas, VA) and
293-hMD2-CD14 stably expressing human MD2 and CD14
genes (InvivoGen, San Diego, CA) and primary culture of lung
fibroblasts prepared from MyD88-/- mice (Oriental Yeast, Tokyo,
Japan) were cultivated in D/F medium (Invitrogen, Carlsbad, CA)
supplemented with 10% FBS. HUVECs (KURABO, Osaka,
Japan) were grown in Humedia-EG (KURABO) medium
containing 2% FBS, FGF-B (5 ng/ml), EGF (10 ng/ml), hydro-
cortisone (1 mg/ml), and heparin (10 mg/ml). HASMCs (KUR-
ABO) were grown in Humedia-SG2 (KURABO) medium
containing 5% FBS, FGF-B (2 ng/ml), EGF (0.5 ng/ml), and
insulin (5.0 mg/ml). Cells at 3,6 passages were used. When
necessary, cells were labeled with
32P- orthophosphate (ICN,
Costa Mesa, CA) at a dose of 100 mCi/ml for 4 h.
Sources of the materials are as follows: Lipopolysaccharide from
E. coli 0111:B4 (LPS, Sigma-Aldrich), lipoteichoic acid from
Staphylococcus aureus (LTA-SA), synthetic bacterial lipoprotein
(Pam3CSK4), peptidoglycan from E. coli 0111:B4 (PGN-EC) and
lipomannan from Mycobacterium smegmatis (LM-MS) (InvivoGen),
polymixin B sulphate (PMB; Indofine Chemical Company,
Hillsborough, NJ), recombinant human TLR2 extracellular
domain (rexTLR2), TLR4 extracellular domain/MD-2
(rexTLR4/MD-2), LPS-binding protein (LBP) and HMGB1
(R&D Systems), AGE (made of BSA; Calbiochem, La Jolla, CA),
cell-permeable peptide set comprising peptides that inhibit human
TIRAP and MyD88 functions (IMGENEX, San Diego, CA),
active types of recombinant MEK1, JNK1, p38a, Akt1, PKCa,
PKCe, PKCd, PKCf, and PKCm (MILLIPORE, Gemini
Crescent Dundee, UK), recombinant IRAK4 (BPS Bioscience,
San Diego, CA), and annexin V-FITC (MBL). A TLR2 ligand
mixture of LTA-SA, Pam3CSK4, PGN-EC and LM-MS at
10 ng/ml each was used to activate TLR2 (TLR2Ls). A mixture of
Figure 5. Schematic diagram of signal transduction from RAGE
and TLR4. Both receptors partially share ligands and adaptor proteins.
TLR4 transduces a signal to NFkB via TIRAP, MyD88 and IRAK4 and to
IRF3 via TRAM and TRIF. RAGE phosphorylated by PKCf upon ligand
binding also uses TIRAP, MyD88 and IRAK4 for signal transduction to
NFkB. Presence of yet unknown signaling pathway from RAGE is still
possible. Simultaneous activation of both receptors resulted in
enhanced activation of NFkB. The signaling machinery is also linked
to Akt and caspase-8, and possibly Rac1.
doi:10.1371/journal.pone.0023132.g005
performed under conditions similar to those described in (A). The results were confirmed by two independent and two related experiments. (C)
Downstream signal transduction from RAGE and TLR4. Experiments were performed under conditions similar to those described in (B). The results
were confirmed by two independent and two related experiments. (D) Induction of cytokines by differential stimulation of RAGE and TLR4 as assayed
by Northern blot analysis. Experiments were performed under conditions similar to those described in (B) except for treatment time (12 h). The results
were confirmed by an independent and four related experiments.
doi:10.1371/journal.pone.0023132.g004
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used to block activation of TLR2 and TLR4 by ligands.
Western Blot Analysis and Immunoprecipitation
Western blot analysis was performed under conventional
conditions. Antibodies used were as follows: mouse anti-HA tag
(clone 6E2), mouse anti-Myc tag (clone 9B11), anti-human IRF-3;
rabbit anti-human RAGE (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-human phospho-IRF-3 (Ser396), rabbit
anti-human p38, rabbit anti-human phospho-p38 (Thr180/
Tyr182), rabbit anti-human SAPK/JNK, mouse anti-human
phospho-SAPK/JNK (Thr183/Tyr185), rabbit anti-human Akt,
rabbit anti-human phospho-Akt (Ser473), rabbit anti-human
IKKa, rabbit anti-human IKKa/b (Ser176/180), rabbit anti-
human IRAK4, rabbit anti-human NFkB (p65), and mouse anti-
human cleaved caspase-8 (Asp384) antibodies (Cell Signaling
Technology, Beverly, MA); rabbit anti-His tag and rabbit anti-
human MyD88 antibodies (MBL, Nagoya, Japan); rabbit anti-
human PKCa, rabbit anti-human PKCe, rabbit anti-human
PKCf, and rabbit anti-human PKCm antibodies (Santa Cruz
Biotechnology); rabbit anti-human DIAPH1 (Dia-1), rabbit anti-
human TIRAP, and mouse anti-TRAM antibodies (Abcam,
Cambridge, MA); and mouse anti-human tubulin antibody
(Sigma-Aldrich). Rabbit anti-human RAGE antibody was bioti-
nylated using a Biotin Labeling Kit-SH (Dojindo Molecular
Technologies, Rockville, MD) to recover antibody-free RAGE
after immunoprecipitation using streptavidin-agarose (Figures. 2D,
3A, S3E and S3F). The second antibody was horseradish-
peroxidase-conjugated anti-mouse or anti-rabbit IgG antibody
(Cell Signaling Technology). Positive signals were detected by a
chemiluminescence system (ECL plus, GE Healthcare Bio-
Sciences, Piscataway, NJ). Rabbit anti-human IL-6 antibody
(Abcam) was used for immunostaining.
Monoclonal Anti-HA (clone HA-7) tag-agarose (Sigma-Aldrich),
monoclonal Anti-His tag (clone 2D8) and monoclonal anti-Myc
tag (clone 1G4) agaroses (MBL), and streptavidin agarose
(Invitrogen) were used for the co-immunoprecipitation experi-
ments.
Northern Blot Analysis
Ten micrograms of total RNA isolated by the acid guanidinium
thiocyanate/phenol-chloroform method was electrophoresed in a
1% agarose gel and transferred to a Nytran Plus nylon membrane
(GE Healthcare Bio-Sciences). Entire coding regions of human IL-
6, IL-8, TNFa, IFNb, and GAPDH genes were used as probes for
Northern blot analysis.
Plasmid Constructs
Human cDNAs, S100A12, HMGB1, and cytoplasmic domain
of RAGE (RAGE(Cyt), 364-404 aa) were cloned into pGEX
vector series (GE Healthcare Bio-Sciences), i.e., S100A12 into
pGEX-6P3, HMGB1 and RAGE(Cyt) into pGEX-6P1.
We made a mammalian expression vector by modifying the
pIDT-SMART cloning vector (Integrated Device Technology,
San Jose, CA) using CMV promoter-intron (CMVi) and a part of
the HTLV type 1 LTR (RU5’) to express even shorter cargo
cDNAs at very high levels. Various combinations of tags at either
the N-terminal (6His-2HA) or C-terminal (Myc-HA-Flag-6His)
side of RAGE and its variant cDNAs were prepared. Since RAGE
is a single-pass type I membrane protein, the tag sequence was put
between the N-terminal region (1–31 aa) including the signal
sequence (1–23 aa) and the remaining part of RAGE cDNA when
constructing N-terminally tagged vectors (Figure. S1F). PKC
isoforms were tagged with C-terminal HA, and TLR adaptor
proteins, TIRAP, MyD88 and TRAM, were tagged with N-
terminal Myc and C-terminal HA.
Recombinant Protein Preparation
Dimerized human S100A11 was prepared as described
previously [15]. Purification of the bacterially expressed GST-
fusion proteins was performed under conventional conditions.
GST was cleaved with PreScission protease (GE Healthcare Bio-
Sciences) when necessary. Endotoxin (LPS and b-glucans)
contaminated in the purified recombinant proteins were deter-
mined by a Limulus Amebocyte Lysate (LAL) assay using a
Limulus test kit (Seikagaku Corporation, Tokyo, Japan). Detected
amounts were as follows: GST, 0.013 EU/mg; HMGB1, 0.017
EU/mg; S100A11, 0.007 EU/mg; S100A12, 0.008 EU/mg; AGE-
BSA (Calbiochem), 0.001 EU/mg; and HMGB1 (R&D), 0.001
EU/mg.
In vitro Kinase Assay
In vitro kinase reaction was performed using active type of
recombinant kinases (50 ng) and purified GST-RAGE(Cyt) (1 mg)
or HEK293-derived RAGE(Cyt) purified by anti-6His tag
antibody agarose (MBL) in the presence of [c-
32P] ATP (HAS,
Budapest, Hungary). To confirm activation of PKCf in cells,
biotinylated-PKCf–specific substrate (Santa Cruz Biotechnology)
was incubated with cell extracts, and then the substrate peptide
was trapped on a streptavidin-coated plate (BD Biosciences
Bedford, MA) and radioactivity was determined.
Assay for Activated NFkB and Rac1
Pull-down assay of NFkB transcription factor bound to the
NFkB-responsive element (NFkB RE) was performed under
conditions reported previously [15]. A biotinylated 22-bp NFkB
RE oligo DNA was prepared using a forward primer (59-biotin-
AGTTGAGGGGACTTTCCCAGGC -39) and a reverse primer
(39-TCAACTCCCCTGAAAGGGTCCG-biotin-59), incubated
with whole cell extracts, and pulled down using a streptavidine
agarose (Invitrogen). Bound NFkB (p65) was determined by
Western blot analysis. GTP-bound form of Rac1 was determined
using a Rac1 Activation Assay Kit (MILLIPORE).
RNA Interference
Validated siRNAs for human PKCa (ID No. s11092) and for
human PKCf (ID No. s11129) and control siRNA (Silencer
Negative control 2 siRNA) were purchased from Ambion (Austin,
TX). Human PKCe (siGENOME SMART pool M-004653-02-
0005), human PKCm (siGENOME SMART pool M-005028-02-
0005), human RAGE (siGENOME SMART pool M-003625-02-
0005) and mouse TIRAP (siGENOME SMART pool M-049112-
00-0005) siRNAs were purchased from Thermo Scientific
Dharmacon (Lafayette, CO). siRNAs were transfected using
Lipofectamin RNAiMAX reagent (Invitrogen).
Supporting Information
Figure S1 Phosphorylation of RAGE and identification
of a responsible kinase. (A and B) Phosphorylation of full-
length RAGE (wt) but not cytoplasmic domain-deleted variant
(DCyt). HEK293 cells were transfected with plasmid constructs of
RAGE-Myc-HA-Flag-6His (wt, closed arrowhead; DCyt, open
arrowhead), and the cells were then treated with 0,100 ng/ml of
recombinant S100A11 protein for 1 h (A: The results were
confirmed by an independent and four related experiments.) or
with 10 ng/ml of the protein for indicated periods (B: The results
were confirmed by an independent and four related experiments.).
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32P]Phosphate-labeled cell extracts were pulled-down with anti-
HA agarose and immunoblotted or analyzed by autoradiography.
(C) Phosphorylation of full-length RAGE (wt) by S100A8/A9.
Experiments were performed under the conditions similar to those
described in Figure 1A. HEK293 cells were exposed to 10 ng/ml
of GST or a mixture of S100A8 and S100A9 recombinant
proteins (S100A8/A9; 10 ng/ml each) for 30 min. +PMB
indicates that the recombinant proteins were preincubated with
polymixin B (10 mg/ml) in order to abrogate possible effect of LPS.
The results were confirmed by three independent experiments. (D)
Phosphorylation of RAGE (Cyt) by recombinant kinases (consti-
tutively active form) in vitro. : The results were confirmed by an
independent and three related experiments. (E) Confirmation of
the specificity of biotinylated PKCf substrate. Recombinant
kinases (constitutively active form) were incubated with the
PKCf-substrate in the presence of [c-
32P]-ATP and the substrate
was trapped on a streptavidin-coated 96-well plate. The
experiment was performed in quadruplicates. (F) Dose-dependent
activation of PKCf by RAGE ligands in RAGE-transfected
HEK293 cells. Experimental conditions were similar to those for
Fig. 1E. Standard deviations were negligible on this scale. The
results were representative of two independent experiments. (G)
Effect of RAGE phosphorylation on co-precipitation with PKC
isoforms. Upper panel: A diagram of N-terminally 6His-2HA-
tagged full-length RAGE. SS, signal sequence; Ext D, extracellular
domain; TMD, transmembrane domain; Cyt D, cytoplasmic
domain. Lower panel: Plasmid constructs of 6His-2HA-RAGE(-
Cyt) variants [SSST (wild-type), ASST (Ser391 to Ala; non-
phosphorylatable), and ESST (Ser391 to Glu; phosphorylation
mimic)] were co-transfected with PKC isoforms (PKCs-HA) into
HEK293 cells. Amounts of PKCs (using upper part of the gel) and
RAGE (using lower part of the gel) were determined with anti-HA
antibody with or without immunoprecipitation with anti-6His
antibody. The results are representative of three independent
experiments. (H) Down-regulation of endogenous PKCf by
siRNA abrogated S100A8/A9 (30 min)-induced phosphorylation
of co-transfected RAGE-Myc-HA-Flag-6His in HEK293 cells.
The results were confirmed by two independent and three related
experiments.
(TIF)
Figure S2 Identification of adaptor proteins for RAGE.
(A) Co-precipitation of TIRAP with RAGE(Cyt). Plasmid
constructs of 6His-2HA-RAGE(Cyt) and Myc-adaptors (MyD88,
TIRAP, or TRAM)-HA were co-transfected into HEK293 cells
and the cell extracts were analyzed by immunoblotting for their
expression (upper panel) and for co-precipitation (lower panel)
after pulling down with anti-6His agarose. The results were
confirmed by two independent and six related experiments. (B)
Effect of RAGE phosphorylation status on binding with adaptor
proteins. Plasmid constructs of 6His-2HA-RAGE(Cyt) variants
(see the legend for Fig. S1F) were co-transfected with Myc-
MyD88-HA and Myc-TIRAP-HA into HEK293 cells and
analyzed in a way similar to that described in (A). Closed
arrowhead, MyD88; open arrowhead, TIRAP. The results were
confirmed by an independent and four related experiments. (C)
Mutation in the TIR domain of TIRAP (
118LQLRDATPG-
GAIV
131S replaced with SQSSSATGGGASGS) and MyD88
(
196RDVLPG
202T replaced with SSGLGGT) abrogated their
binding to 6His-2HA-RAGE(Cyt) in co-transfected HEK293 cells.
W, wild-type; M, mutated. Closed arrowhead, MyD88; open
arrowhead, TIRAP. The results were confirmed by three
independent and five related experiments. (D) No effect of AGE
on expression levels of MyD88 and TIRAP in TIRAP-down
regulated NIH3T3 cells and MyD88-/- fibroblasts, respectively.
Mouse TIRAP siRNA was applied at 10 nM for 48 h. The results
were confirmed by an independent and a related experiments.
(TIF)
Figure S3 Activation of endogenous RAGE and its
biological consequence in HUVECs. (A) Expression levels
of endogenous RAGE in normal human keratinocytes (NHK),
HUVECs, and HASMCs determined by Western blot analysis.
The results were representative of four independent experiments.
(B and C) Intracellular signal transduction triggered in HUVECs
treated with AGE at different doses (B) and for different periods
(C). The results were confirmed by an independent and two
related experiments. (D) Inhibition of AGE-induced nuclear
translocation of NFkB by cell-permeable inhibitory peptides for
MyD88 and TIRAP (100 mM) in HUVECs. The results are
representative of two independent experiments. (E) Immunopre-
cipitation with biotinylated anti-RAGE antibody enabled to
recover RAGE protein without contamination with the first
antibody. The results were confirmed by two independent and
three related experiments. (F and G) Effect of interference with
functions of downstream molecules on signaling triggered from
activated endogenous RAGE and TLR. Cell-permeable inhibitory
peptides (100 mM) for TIRAP and MyD88 or siRNAs (10 nM) for
PKCf were applied 12 h or 48 h prior to stimulation with AGE
(100 mg/ml for 1 h) or LPS (100 ng/ml for 1 h). BSA was used as
a control. The results were confirmed by an independent and two
related experiments (F) or by an independent and three related
experiments (G). (H) Activation of PKCf on stimulation of
endogenous RAGE with various ligands. Experiments were
performed under the conditions similar to those described in the
legend for Figs. 3A, 3B and 1E. The results were confirmed by an
independent experiment. (I) Induction of apoptosis by AGE in
HUVECs was abrogated by inhibiting TIRAP, MyD88 or PKCf.
HUVECs were treated with 100 mg/ml AGE for 48 h. Cell-
permeable inhibitory peptides (100 mM) were added at 12 h prior
to and twice during the treatment with AGE. siRNA for PKCf
was applied 24 h prior to application of AGE. Experiments were
performed under serum-free conditions but in the presence of
supplements. Apoptosis was determined by staining with annexin
V-FITC. The experiment was performed in triplicates. The results
were confirmed by an independent experiment.
(TIF)
Figure S4 Analysis of differential stimulation of RAGE
and TLR4. (A) Intracellular signal transduction triggered by
ligands stimulating overexpressed 6His-2HA-RAGE and TLR4-
Myc in 293-hMD2-CD14 cells examined under conditions
described in Fig. 4A. Open triangle, TLR4; closed triangle,
RAGE. The results were confirmed by two independent and three
related experiments. (B) Expression of RAGE-Myc-HA-Flag-6His
and TLR4-Myc (w, wild-type; D, cytoplasmic domain-deleted) in
293-hMD2-CD14 cells determined using anti-Myc antibody. The
results were confirmed by two independent and three related
experiments. (C) Expression of RAGE-Myc-HA-Flag-6His and
TLR4-Myc (w, wild-type; D, cytoplasmic domain-deleted) in 293-
hMD2-CD14 cells treated with AGE (100 mg/ml) and other
agents (100 ng/ml), as assayed by immunoprecipitation followed
by Western blotting using anti-Myc antibody. The results were
confirmed by two independent and three related experiments. (D)
Abrogation of the effect of LPS but not of AGE by polymixin B
(PMB). Experiments were performed under conditions similar to
Figs. 4B and 4C. Open triangle, TLR4; closed triangle, RAGE.
The results were confirmed by an independent and three related
experiments.
(TIF)
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transduction upon S100A8/A9 stimulation. (A) Intracellu-
lar signal transduction triggered by ligands in 293-hMD2-CD14
cells overexpressed 6His-2HA-RAGE and TLR4-Myc under same
conditions described in Fig. S4A. The transfected cells were
treated with control BSA (100 mg/ml), LBP-LPS (100 ng/ml each,
preincubated for 2 h), AGE (100 mg/ml), HMGB1-LPS (100 ng/
ml each, preincubated for 2 h), and S100A8/A9 (100 ng/ml each)
for 30 min. Open triangle, TLR4; closed triangle, RAGE. The
results were confirmed by two independent and three related
experiments. (B) Co-precipitation of endogenous adaptor proteins
with full-length 6His-2HA-RAGE (wt) and TLR4 (wt)-Myc
transfected into 293-hMD2-CD14 cells were performed under
the conditions similar to those described in Fig. 4A. Cell extracts
were pulled down with anti-Myc + anti-HA, anti-Myc, or anti-HA
agarose and immunoblotted with indicated antibodies. Open
triangle, TLR4; closed triangle, RAGE as corresponding to (A).
The results were confirmed by two independent and two related
experiments. (C) Co-precipitation of endogenous adaptor proteins
with RAGE-Myc-HA-Flag-6His and TLR4-Myc (w, wild-type; D,
cytoplasmic domain-deleted variant) in 293-hMD2-CD14 cells
treated with the same series of agents indicated in (A) and (B).
Experiments were performed by immunoprecipitation followed by
Western blotting using anti-Myc antibody as described in Figs.S4C
and 4B. The results were confirmed by two independent and two
related experiments. (D) Downstream signal transduction from
RAGE and TLR4 stimulated with S100A8/A9. Experiments were
performed under the conditions similar to those described in
Fig. 4C. The results were confirmed by two independent and three
related experiments.
(TIF)
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